Canada Markets close in 5 hrs 45 mins

Iterum Therapeutics plc (ITRM)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.4300-0.0200 (-1.38%)
As of 10:15AM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close1.4500
Open1.4500
Bid1.4200 x 2200
Ask1.4500 x 1400
Day's Range1.4158 - 1.4500
52 Week Range0.6010 - 7.0500
Volume7,265
Avg. Volume372,486
Market Cap261.368M
Beta (5Y Monthly)1.40
PE Ratio (TTM)N/A
EPS (TTM)-2.1660
Earnings DateAug 12, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Iterum Therapeutics Reports Employment Inducement Grant

    DUBLIN, Ireland and CHICAGO, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (“Iterum Therapeutics”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that it has granted a non-statutory share option to purchase an aggregate of 2,500 ordinary shares of Iterum Therapeutics as an inducement to a newly hir

  • GlobeNewswire

    Iterum Therapeutics announces Issuance of Allowance for a U.S. Patent Covering Oral Sulopenem

    DUBLIN, Ireland and CHICAGO, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the United States Patent and Trademark Office (“USPTO”) has issued Iterum a Notice of Allowance for U.S. patent application number 16/372,075 en

  • GlobeNewswire

    Iterum Therapeutics Reports Third Quarter 2022 Financial Results

    --Patient Enrollment in Registration Trial for uUTI Underway-- --Cash Runway into 2024-- DUBLIN, Ireland and CHICAGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (“Iterum”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the third quarter ended September 30, 2022. “We are thri